Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program
Lead AMHR2 agonist compound demonstrates high specific activity in biological assays and desired pharmacokinetic profile in preclinical animal studies NEW YORK--(BUSINESS WIRE)--Celmatix Inc. a biotechnology company focused on ovarian biology, today anno